For the diabetes patients using insulin, daily used needles has a critical influence on the treatment effect and the patients' quality of life. Maxmind has signed cooperation agreement with HTBT, one of the leading insulin technology and products provider in China, to bring the world’s smallest 34g needle manufacturer by Terumo Japan to China market to benefit the vast number of diabetic patients.
工欲善其事必先利其器，34G针头具备如下优势： Advanced technology is premise to guarantee advanced quality. The Terumo 34G needle has the following advantages:
1) 34G needle is the world's smallest needle (34G refers to the number of needles can be placed in a square meter); 2) asymmetrical blade tip of willow leaf shape is more sharp; 3) designing of double-sided conical needle tube to reduce resistance; 4) only 4mm long needle is safe and convenient, which is more suitable for Asian skin thickness. 5) the experimental data proved that 50% reduction of wound size after needle injection directly affects the generation of subcutaneous fat hyperplasia (subcutaneous fat hyperplasia exists in form of subcutaneous nodules). 6) Manufactured by Terumo Japan, awarded Good Design Award by Japan Industry Design Revitalization association.
Terumo Corporation, founded in 1921, headquartered in Shibuya district, Tokyo, Japan, is a large enterprise in medical equipment and pharmaceutical products. Products include disposable medical instruments, blood transfusion devices series, medical drugs and nutrition drugs series, angiography and treatment catheters, medical electronic products series, artificial heart and lung products series, infusion pumps, injection pumps, blood transfusion pumps, anesthesia pumps, target control pumps series, inspection products series, family health care products series. Expected 597 billion yen ($5.2 billion) of operating income in 2018.
